Skip to search formSkip to main contentSkip to account menu

CEV regimen

Known as: Cytoxan-Etoposide-Vincristine Regimen, VEC regimen 
A regimen consisting of cyclophosphamide, etoposide and vincristine used for the treatment of extensive-stage small cell lung cancer.
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2016
Highly Cited
2016
PURPOSE Combining immunotherapeutic agents with different mechanisms of action may enhance efficacy. We describe the safety and… 
Review
2016
Review
2016
Many mammalian viruses have properties that can be commandeered for the treatment of cancer. These characteristics include… 
Highly Cited
2016
Highly Cited
2016
9568Background: T-VEC is a herpes simplex virus (HSV)-1 -based oncolytic immunotherapy designed to selectively replicate in… 
Highly Cited
2015
Highly Cited
2015
PURPOSE Talimogene laherparepvec (T-VEC) is a herpes simplex virus type 1-derived oncolytic immunotherapy designed to selectively… 
Highly Cited
2015
Highly Cited
2015
Fifteen patients with treatment-refractory colorectal cancer were enrolled on a phase 1b study of Pexa-Vec (pexastimogene… 
Highly Cited
2013
Highly Cited
2013
Oncolytic viruses and active immunotherapeutics have complementary mechanisms of action (MOA) that are both self amplifying in… 
Review
2013
Review
2013
Oncolytic viruses (OVs) are tumor-selective, multi-mechanistic antitumor agents. They kill infected cancer and associated… 
Review
2013
Review
2013
LBA9008 Background: T-VEC is an oncolytic immunotherapy (OI) derived from herpes simplex virus type-1 designed to selectively… 
Review
1995
Review
1995
A total of 83 patients with nonorgan-confined bladder cancer with or without lymph node metastases (tumor stages pT3b, pT4a and…